lymphoid cells

[Blood] Scientists analyzed the effect of decitabine on T-cell subpopulations in immune thrombocytopenia in vitro and in vivo. They found that low-dose decitabine promoted the generation and differentiation of regulatory T cells and augmented their immunosuppressive function.

[Genentech] Genentech announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1, as determined by a US FDA-approved test.

[Cancer Gene Therapy] The authors discuss the importance of oncolytic viruses-based combination therapies in optimizing antiviral and antitumor innate immune responses stimulated by virotherapy toward tumor eradication, and how these processes vary depending on the tumor and oncolytic viruses in question.

[Science Translational Medicine] Using an immunocompetent mouse model expressing a humanized CD3ε chain and bispecific T cell engager (BiTE) molecules directed against mouse CD19, mouse CLDN18.2, or human EPCAM antigens, researchers investigated the pharmacokinetic and pharmacodynamic parameters and immune correlates associated with BiTE efficacy across multiple syngeneic solid-tumor models.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists investigated whether and how factors that modulate T cell responsiveness to antigenic stimuli influence PD-1 function.

[Journal of Experimental Medicine] Investigators developed new transgenic mice to profile pulmonary GM-CSF expression, which they detected in both immune cells, including group 2 innate lymphoid cells and γδ T cells, as well as AT2s.